What Ascidian Therapeutics does

Ascidian Therapeutics is a clinical-stage biotechnology company developing a first-of-its-kind RNA exon editing platform to treat the underlying genetic causes of diseases by replacing disease-causing exons with wild-type exons at the RNA level, without modifying DNA. The platform is inspired by ascidian (sea squirt) trans-splicing biology and is built around pre-mRNA trans-splicing combined with high-throughput molecular biology, computational biology, structure-based RNA design, and an AI/ML-enabled RNA discovery engine. The lead therapeutic candidate, ACDN-01, is a single-AAV-vector RNA exon editor for ABCA4 retinopathies including Stargardt disease and is currently in the Phase 1/2 STELLAR trial, with adult dose escalation completed and pediatric expansion underway; preclinical pipeline includes an MSH3 splice-modulation program targeting Huntington's disease and other repeat expansion disorders.

The company is headquartered in Boston, MA, employs 11-50 people, and is backed by Apple Tree Partners, which founded the company in October 2022 and led both the $50M Series A and $40M Series A extension. Ascidian's business model is built on strategic research collaborations and licensing agreements with major pharmaceutical companies rather than direct product sales. Key deals include a June 2024 collaboration with Roche (up to $1.8B with $42M upfront) for neurological diseases and a June 2026 collaboration with Eli Lilly (up to $1.9B) for inherited kidney diseases, with Lilly and Roche handling clinical development, manufacturing, and commercialization for partnered indications. Manufacturing for ACDN-01 is supported by a January 2026 partnership with Forge Biologics using its cGMP FUEL platform. Customer segments are disease-defined (Stargardt/ABCA4 retinopathies, neurological diseases, monogenic kidney diseases, neuromuscular disorders), and pricing for any future approved therapeutics is not publicly disclosed as the company remains pre-revenue.

Name

Ascidian Therapeutics

Legal name

Ascidian Therapeutics, Inc.

Website

https://ascidian-tx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Ascidian Therapeutics is a clinical-stage biotechnology company developing RNA exon editing therapeutics for genetic diseases. Its lead program, ACDN-01, targets Stargardt disease, with partnered programs in neurological and kidney diseases via Roche and Eli Lilly.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)

Keywords

• RNA exon editing
• Gene therapy
• RNA therapeutics
• Clinical-stage biotechnology
• Genetic disease treatment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Strategic Partnerships and Licensing: Ascidian generates revenue through strategic research collaborations and licensing agreements with major pharmaceutical companies. These deals include upfront payments, development and commercial milestones, and royalties. Notable deals include Eli Lilly partnership (up to $1.9B for kidney diseases) and Roche partnership (up to $1.8B for neurological diseases).
2. Future Drug Commercialization: Pre-revenue clinical stage company. Future revenue potential from commercialization of RNA exon editing therapeutics, including ACDN-01 for Stargardt disease and other pipeline programs in retinal, neurological, neuromuscular, and kidney disease indications.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

Ascidian Therapeutics develops RNA exon editing therapeutics that replace disease-causing exons with wild-type exons at the RNA level using pre-mRNA trans-splicing technology. The platform enables treatment of large genes and genes with high mutational variance that are beyond the reach of existing DNA editing approaches, without modifying DNA or requiring foreign enzymes. Its lead candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials.

Product overview

Ascidian Therapeutics is developing a new class of RNA exon editing therapeutics to treat the underlying causes of genetic diseases. The company's platform technology enables editing and replacement of disease-causing RNA exons, producing full-length functional proteins. The lead therapeutic candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials. Additional programs include MSH3 for Huntington's disease and repeat expansion disorders. Partnered programs with Roche (neurological diseases) and Eli Lilly (kidney diseases) leverage the platform for additional therapeutic areas. The company operates with manufacturing partnerships including Forge Biologics for cGMP production.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Completed dose escalation portion of Phase 1/2 STELLAR trial with 10 adult participants ages 18-77
• +2 more outcomes

Named customers2 records

Segments4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Eli LillyflagshipStrategic or Co-development Partner · 3 June 2026Global research and licensing agreement worth up to $1.9 billion for discovery and development of RNA exon editing therapies for kidney diseases. Ascidian leads discovery and selected preclinical activities while Lilly handles clinical development, manufacturing, and commercialization with exclusive rights to Ascidian's exon editing platform for undisclosed kidney disease targets. The partnership targets monogenic kidney diseases affecting over 3.5 million Americans.
• Forge BiologicscoreTechnology or Integration · 7 January 2026Strategic manufacturing partnership for ACDN-01, Ascidian's lead RNA exon editing therapy for Stargardt disease. Forge Biologics provides process development, toxicology, and cGMP manufacturing services using proprietary FUEL platform at its 200,000-square-foot facility in Columbus, Ohio.
• RocheflagshipStrategic or Co-development Partner · 18 June 2024Partnership potentially worth up to $1.8 billion for discovery and development of RNA exon editing therapeutics targeting neurological diseases. Ascidian received $42 million upfront payment from Roche for the neuro-focused collaboration, with potential additional milestone and royalty payments.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ProQR Therapeutics: RNA-focused biotech developing Axiomer RNA editing technology and other RNA-based therapies for inherited retinal diseases and other genetic disorders. Direct competitor in RNA editing for ophthalmology indications.
• Stoke Therapeutics: Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies that increase protein production by modulating RNA splicing, including for genetic diseases such as Dravet syndrome. Direct competitor in RNA-targeted precision medicines for genetic disorders.
• Wave Life Sciences: Clinical-stage RNA therapeutics company developing RNA editing and splice-modulating oligonucleotides for genetic diseases. Direct competitor in RNA-targeted modalities with similar programs in ophthalmology and rare genetic diseases.

Emerging players

• SpliceBio: Clinical-stage company developing gene therapies based on protein trans-splicing (similar biological concept to Ascidian's RNA trans-splicing). Direct mechanistic parallel in exon replacement for genetic diseases.
• Dyne Therapeutics: Clinical-stage company developing oligonucleotide therapies for muscle diseases, founded by Romesh Subramanian (also Ascidian's co-founder). Closely related through founder DNA and overlapping RNA-based therapeutic platform.
• Shape Therapeutics: Preclinical RNA editing company leveraging AI/ML-based platform for RNA-targeted therapies. Competes with Ascidian's AI-enabled RNA discovery platform in computational RNA therapeutic design.
• Korro Bio: Preclinical/early clinical company developing RNA editing therapeutics using ADAR-mediated approaches for genetic diseases. Competes with Ascidian in the RNA editing modality space, focused on high-throughput platform-based RNA editing.

Broad incumbents

• Beam Therapeutics: Clinical-stage company developing base editing and prime editing therapies for genetic diseases. Competes in the broader genetic medicine editing space where Ascidian's exon editing is positioned as a complementary modality for large-gene targets.
• Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies for genetic diseases. Represents the incumbent DNA-editing approach that Ascidian's RNA exon editing is positioned to complement for large-gene targets.
• Editas Medicine: Clinical-stage CRISPR-based gene editing company with programs in ophthalmology and genetic diseases. Competes in the broader genomic medicine space where Ascidian's RNA exon editing offers a non-DNA editing alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ascidian-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascidian Therapeutics